GleamWall
中文EN

IMMX Immix Biopharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1873835 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-96.3%
TTM EPS YoY-7.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-26.9%
ROA-25.3%
ROIC (approx.)-1,121.6%
Asset turnover—

Leverage & solvency

Liabilities / assets3.1%
Debt / equity0.00x
Current ratio33.72x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.97x
Accruals ratio-0.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$5.54M$5.33M$5.98M$5.73M$4.58M$3.97M$1.98M$1.37M
SG&A expense$10.40M$7.12M$4.82M$5.17M$3.08M$2.75M$2.71M$3.61M
Operating income-$15.95M-$12.46M-$10.80M-$10.89M-$7.66M-$6.72M-$4.68M-$4.99M
Pretax income-$13.93M-$11.54M-$10.09M-$10.68M-$7.58M-$6.61M-$4.53M-$4.80M
Income tax$0$14,322—$11,266$7,722$8,914$9,822$10,785
Net income-$13.93M-$11.56M-$10.09M-$10.69M-$7.59M-$6.62M-$4.54M-$4.81M
EBITDA-$15.85M-$12.37M-$10.71M-$10.84M-$7.57M-$6.66M-$4.64M-$4.97M
EPS (basic)-0.19-0.18-0.18—-0.24-0.22-0.15—
EPS (diluted)-0.19-0.18-0.18—-0.24-0.22-0.15—
Weighted avg. shares (diluted)74.09M63.77M55.37M—31.93M29.98M29.70M—
Balance sheet
Cash & equivalents$320.32M$225.49M$79.25M$93.93M$15.95M$11.64M$15.92M$17.68M
Short-term investments$15.99M$6.62M$11.33M$6.48M————
Current assets$338.08M$233.79M$92.27M$101.24M$16.58M$12.33M$16.78M$20.20M
PP&E, net$2.41M$2.36M$2.43M$2.52M$2.36M$2.23M$2.12M$1.74M
Total assets$345.95M$239.11M$95.82M$104.84M$20.08M$15.64M$19.89M$22.95M
Current liabilities$10.03M$9.30M$10.54M$10.11M$10.85M$10.01M$9.31M$8.69M
Total liabilities$10.89M$10.19M$11.45M$11.04M$11.82M$10.98M$10.30M$9.70M
Shareholders' equity$335.06M$228.92M$84.36M$93.80M$8.26M$4.65M$9.59M$13.25M
Shares outstanding83.81M71.54M53.01M52.95M33.04M28.41M27.85M27.54M
Cash flow statement
Operating cash flow-$12.31M-$11.74M-$9.83M-$11.03M-$5.91M-$5.31M-$1.69M-$1.48M
Capital expenditure$121,241$21,043$32,486$165,126$372,456$127,630$67,713$507,151
Free cash flow-$12.43M-$11.76M-$9.86M-$11.19M-$6.28M-$5.44M-$1.75M-$1.98M
Investing cash flow-$12.03M$2.67M-$4.80M-$6.65M-$372,456-$127,630-$67,713-$507,151
Financing cash flow$119.17M$155.28M-$37,561$95.67M$10.61M——$0
Depreciation & amortization$94,293$90,993$91,577$52,114$96,986$58,494$38,153$20,603
Stock-based compensation$0$978,140$575,565$570,796$470,471$532,249$868,359$705,653

Free plan shows the latest 8 periods; Pro shows all 23 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.